It has been reported that the inhibition of CHK1, CHK2 or WEE1, as monotherapy or in combination with DNA damaging agents, reduces cell viability and induces apoptosis in preclinical models of ALL [15,16,17,18,19,20]. The gene discussed is CHEK1; the disease is acute lymphoblastic leukemia.